ENOn September 21, 2026, the first participant was officially enrolled at University Hospital Cologne in the landmark clinical study CABA-MiTRA-AFNET12-DZHK34, initiated by the Atrial Fibrillation Network (AFNET) in collaboration with the German Center for Cardiovascular Research (DZHK). This major research project aims to establish whether performing catheter ablation in patients with atrial fibrillation following successful catheter-based mitral valve repair provides superior protection against strokes, heart failure, and premature death compared to standard guideline-based medication. The findings of this study have the potential to refine international cardiology guidelines for older cardiovascular patients.
Understanding Mitral Regurgitation and Atrial Fibrillation
Mitral valve regurgitation stands as the most frequent heart valve disorder encountered among older adults today. In affected individuals, the leaflets of the mitral valve fail to close tightly, allowing blood to flow backward from the left ventricle into the left atrium during cardiac contraction. Over time, this abnormal regurgitant volume leads to chronic pressure and volume overload, ultimately causing progressive structural remodeling and enlargement of the left atrial chamber.
The resulting structural alterations within the atrium create an ideal substrate for the development and maintenance of atrial fibrillation. As the most common cardiac arrhythmia in adults, atrial fibrillation is characterized by rapid, disorganized electrical signals that cause the upper heart chambers to quiver rather than contract effectively. This irregular heart rhythm significantly elevates the risk of intra-cardiac blood clot formation, embolic stroke, progressive heart failure, and overall cardiovascular mortality.
In elderly populations, mitral valve regurgitation and atrial fibrillation frequently co-exist and interact through complex pathophysiological mechanisms. Given the global demographic shift toward an aging population, alongside contributing health factors such as obesity and hypertension, the prevalence of patients suffering from both conditions is projected to increase substantially, underscoring the urgent need for optimized therapeutic management strategies.
Contemporary Treatment Strategies in German Hospitals
Modern cardiovascular centers in Germany employ comprehensive diagnostic panels to evaluate valvular dysfunction and complex rhythm disorders, including high-resolution echocardiography, extended ambulatory electrocardiogram monitoring, and specialized electrophysiological mapping. For patients with severe mitral valve regurgitation, minimally invasive transcatheter mitral valve repair has become an established interventional standard, repairing the defective valve via a catheter without requiring open-heart surgery or cardiopulmonary bypass.
To manage co-existing atrial fibrillation and restore stable sinus rhythm, clinicians typically choose between long-term antiarrhythmic drug therapy and catheter ablation procedures. During catheter ablation, electrophysiologists utilize advanced cardiac mapping and specialized catheters to deliver localized thermal energy to targeted atrial tissue, electrically isolating the abnormal tissue zones responsible for initiating and perpetuating the arrhythmia.
Although catheter ablation is a well-established intervention, it has historically been performed less frequently in elderly individuals with multiple chronic health conditions. Until recently, limited evidence from randomized controlled clinical trials existed regarding the specific efficacy and long-term safety of catheter ablation in patients who have previously undergone transcatheter repair of a severe mitral valve defect.
The CABA-MiTRA Clinical Trial and Its Innovations
The CABA-MiTRA study, which stands for Catheter Ablation for Atrial Fibrillation in Patients with Severe Mitral Regurgitation after Successful Transcatheter Mitral Valve Repair, is led by AFNET Board Member Prof. Stephan Willems of Hamburg, alongside AFNET Steering Committee members Prof. Lars Eckardt of Münster, Prof. Daniel Steven of Cologne, and Prof. Reza Wakili of Frankfurt. This investigator-initiated trial plans to enroll 956 eligible patients across approximately 50 clinical centers in Germany and Europe who have undergone successful mitral valve repair within the preceding six months.
Upon enrollment, trial participants are randomly assigned in a one-to-one ratio to receive either catheter ablation for their atrial fibrillation or standard guideline-based pharmacological treatment. To better understand how reducing the overall duration of irregular heart rhythms prevents cardiovascular complications, a specialized substudy employs miniature implantable event recorders at selected trial sites, allowing researchers to precisely quantify the exact atrial fibrillation burden over extended observation periods.
This multi-center trial receives financial and infrastructure support from the German Center for Cardiovascular Research (DZHK), the German Heart Foundation, and industry partners including Abbott Medical, Boston Scientific, and Biosense Webster / Johnson & Johnson. As emphasized by Prof. Wakili and Prof. Steven, this collaborative scientific effort will generate crucial comparative data to clarify whether proactive rhythm control through ablation offers superior patient outcomes.
Medical Significance and Guidance for Patients Seeking Care
For international patients considering specialized cardiovascular care in Germany, the initiation of the CABA-MiTRA-AFNET12-DZHK34 study highlights the country’s leading role in integrating interventional cardiology and cardiac electrophysiology. Both transcatheter mitral valve repair and catheter ablation are fully approved, highly refined clinical interventions performed routinely by experienced medical teams adhering to rigorous quality standards.
Patients who have received treatment for mitral valve regurgitation and continue to experience symptomatic atrial fibrillation are encouraged to engage in detailed discussions with their attending cardiologists. Important topics to review include the current structural health of the left atrium, the suitability of continuous rhythm monitoring devices, and the comparative risks and benefits of catheter ablation versus ongoing antiarrhythmic medication.
As noted by Prof. Eckardt, the definitive results produced by this landmark clinical study have the potential to shape future therapeutic guidelines worldwide. By establishing clearer evidence-based pathways, clinicians hope to enhance long-term stroke prevention, reduce heart failure hospitalizations, and foster healthier aging for patients facing complex cardiovascular conditions.